TABLE 1.
Demographics and baseline characteristics (safety set)
| Ecleralimab 4 mg (n=15) | Placebo (n=13) | |
| Age (years) | 34.1±10.9 | 34.1±12.6 |
| Female | 8 (53) | 9 (69) |
| Body mass index (kg·m−2) | 26.8±3.9 | 23.7±2.3 |
| FEV1 (L) | 3.4±0.6 | 3.3±0.5 |
| FEV1 (% pred) | 91.0±10.6 | 92.1±15.5 |
| Methacholine PC20 (mg·mL−1)# | 1.41 (272) | 1.37 (136) |
| FENO (ppb)# | 44.02 (89) | 32.20 (72) |
| Blood eosinophils (×109 L−1)# | 0.23 (91) | 0.16 (80) |
| Sputum eosinophils (%)# | 1.97 (101) | 2.19 (135) |
| Inhaled allergen | ||
| Animal dander | 7 (46.6) | 7 (53.8) |
| House dust mite | 3 (20.0) | 0 (0) |
| Grass | 1 (6.7) | 1 (7.7) |
| Tree | 3 (20.0) | 5 (38.5) |
| Crops | 1 (6.7) | 0 (0) |
Data presented as mean±sd or n (%), unless otherwise stated. #: geometric mean (geometric coefficient of variation %). BMI: body mass index; FEV1: forced expiratory volume in 1 s; PC20: provocative concentration causing a 20% decrease in FEV1; FENO: fractional exhaled nitric oxide.